surmount-1 trial tirzepatide non-diabetic weight loss once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 GLP-1 Agonists For Obesity In

Both versions use the same medication, semaglutide, so they come with very similar safety profiles and potential side effects

Bloomer RJ, et al

This review is based on publicly available information including customer complaints filed with Better Business Bureau (verified complaint data accessed January 22, 2026), customer reviews on Trustpilot, ConsumerAffairs, and RealReviews (accessed January 2026), legal filings and analysis, and company-published materials including Terms of Service and website content

D.AndersonG

Our approach involves a thorough evaluation to determine eligibility, followed by a customized treatment plan